UroGen Pharma Q4 2023 Earnings Report

UroGen Pharma EPS Results

• Actual EPS: -$0.72
• Consensus EPS: -$0.67
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

UroGen Pharma Revenue Results

• Actual Revenue: $23.53 million
• Expected Revenue: $22.30 million
• Beat/Miss: Beat by +$1.23 million
• YoY Revenue Growth: N/A

UroGen Pharma Announcement Details

• Quarter: Q4 2023
• Date: 3/14/2024
• Time: N/A

UroGen Pharma (NASDAQ:URGN), a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.